CGON CG Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1991792 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY183.6%
TTM net income YoY-56.8%
TTM EPS YoY-34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,293.5%
Net margin-3,851.1%
FCF margin-3,068.0%
EBITDA margin-4,237.7%
Returns
ROE-28.3%
ROA-26.7%
ROIC (approx.)-26.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.3%
Debt / equity0.00x
Current ratio21.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue30.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.60M | $1.16M | $1.08M | $2.32M | $1.67M | $0 | $52,000 | $456,000 |
| Cost of revenue | $2.67M | — | — | — | $1.58M | — | — | — |
| Gross profit | -$1.06M | — | — | — | $89,000 | — | — | — |
| R&D expense | $39.22M | $54.66M | $43.73M | $29.96M | $27.88M | $31.33M | $27.47M | $26.80M |
| SG&A expense | $22.96M | $28.98M | $20.78M | $17.99M | $23.33M | $17.41M | $14.79M | $11.71M |
| Operating income | -$63.25M | -$86.40M | -$66.39M | -$48.70M | -$51.13M | -$48.74M | -$42.20M | -$38.05M |
| Net income | -$56.89M | -$79.06M | -$60.20M | -$41.31M | -$43.81M | -$41.43M | -$34.45M | -$31.80M |
| EBITDA | -$62.35M | -$85.55M | -$65.55M | -$47.85M | -$51.03M | -$48.59M | -$42.18M | -$38.05M |
| EPS (basic) | -0.64 | -0.90 | -0.71 | — | -0.57 | -0.54 | -0.45 | — |
| EPS (diluted) | -0.64 | -0.90 | -0.71 | — | -0.57 | -0.54 | -0.45 | — |
| Weighted avg. shares (diluted) | 88.87M | 88.20M | 84.52M | — | 76.73M | 76.23M | 76.19M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $28.25M | $19.64M | $33.70M | $32.49M | $45.15M | $14.62M | $41.47M | $257.07M |
| Short-term investments | $956.21M | $1.01B | $1.04B | $709.66M | $635.12M | $646.43M | $646.96M | $484.93M |
| Receivables | $666,000 | $417,000 | $1.27M | $688,000 | $515,000 | — | — | $0 |
| Inventory | $1.17M | $1.00M | $1.49M | $1.56M | $1.50M | — | — | $0 |
| Current assets | $1.01B | $1.05B | $1.10B | $759.48M | $695.79M | $673.03M | $701.19M | $754.21M |
| PP&E, net | $14.93M | $14.71M | $15.07M | $15.60M | $15.33M | $253,000 | $264,000 | $272,000 |
| Goodwill | $10.30M | $10.30M | $10.30M | $10.30M | $12.80M | — | — | $0 |
| Intangibles | $530,000 | $545,000 | $560,000 | $575,000 | $1.67M | — | — | $0 |
| Total assets | $1.05B | $1.09B | $1.14B | $791.59M | $729.91M | $701.45M | $728.18M | $754.80M |
| Current liabilities | $46.43M | $47.24M | $35.22M | $30.84M | $30.53M | $30.38M | $22.64M | $21.37M |
| Long-term debt | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | — | — | $0 |
| Total debt | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | — | — | $0 |
| Total liabilities | $55.70M | $56.54M | $43.48M | $38.99M | $42.27M | $31.09M | $23.42M | $21.42M |
| Shareholders' equity | $990.97M | $1.03B | $1.09B | $752.60M | $687.64M | $670.36M | $704.76M | $733.38M |
| Net debt | -$25.25M | -$16.64M | -$30.70M | -$29.49M | -$42.15M | — | — | -$257.07M |
| Shares outstanding | 89.30M | 88.31M | 88.01M | 80.69M | 78.28M | 76.23M | 76.22M | 76.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$47.71M | -$46.41M | -$56.94M | -$36.22M | -$38.89M | -$27.96M | -$29.28M | -$20.66M |
| Capital expenditure | $1.11M | $468,000 | $304,000 | $7,000 | $97,000 | $14,000 | $16,000 | $209,000 |
| Free cash flow | -$48.82M | -$46.88M | -$57.25M | -$36.22M | -$38.99M | -$27.97M | -$29.29M | -$20.87M |
| Investing cash flow | $46.03M | $30.43M | -$334.85M | -$75.50M | $15.04M | $1.41M | -$186.77M | $10.90M |
| Financing cash flow | $10.28M | $1.92M | $393.00M | $99.07M | $54.37M | -$296,000 | $450,000 | $223.41M |
| Depreciation & amortization | $900,000 | $850,000 | $841,000 | $849,000 | $100,000 | $156,000 | $24,000 | $0 |
| Stock-based compensation | $8.46M | $14.33M | $6.47M | $7.19M | $7.33M | $7.01M | $5.15M | $4.99M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.